TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Detection and Intervention for the Prevention of Psychosis Project
Brief Summary: EDIPP is a multisite trial of early identification and intervention to prevent the onset of psychosis in adolescents and young adults, carried out at six sites across the United States. The hypothesis is that very early identification and intervention will be effective in delaying or preventing onset of psychosis and improving social and occupational functioning.


Options:
A: Arm Label: BI 409306; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 409306; Assigned to Arm(s): BI 409306 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Family Focused Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Family Focused Treatment | Arm Label: Enhanced Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Care | Intervention Type: BEHAVIORAL; Name: Family Focused Treatment; Assigned to Arm(s): Family Focused Treatment | Intervention Type: BEHAVIORAL; Name: Enhanced Care; Assigned to Arm(s): Enhanced Care
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Family-aided Assertive Community Treatment; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Behavioral: Psychoeducational multifamily group treatment, Behavioral: Supported employment and education | Intervention Type: DRUG; Name: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Psychoeducational multifamily group treatment; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Supported employment and education; Assigned to Arm(s): Family-aided Assertive Community Treatment
D: Arm Label: Integrated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Treatment | Arm Label: Community Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Care | Intervention Type: BEHAVIORAL; Name: Integrated Treatment; Assigned to Arm(s): Integrated Treatment | Intervention Type: BEHAVIORAL; Name: Community Care; Assigned to Arm(s): Community Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Detection and Intervention for the Prevention of Psychosis Project
Brief Summary: EDIPP is a multisite trial of early identification and intervention to prevent the onset of psychosis in adolescents and young adults, carried out at six sites across the United States. The hypothesis is that very early identification and intervention will be effective in delaying or preventing onset of psychosis and improving social and occupational functioning.


Options:
A: Intervention Type: PROCEDURE; Name: Individual placement and support (vocational rehabilitation); Assigned to Arm(s): N/A
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Family-aided Assertive Community Treatment; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Behavioral: Psychoeducational multifamily group treatment, Behavioral: Supported employment and education | Intervention Type: DRUG; Name: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Psychoeducational multifamily group treatment; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Supported employment and education; Assigned to Arm(s): Family-aided Assertive Community Treatment
C: Arm Label: Functional remediation; Type: EXPERIMENTAL; Interventions: Behavioral: Functional remediation | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducation | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Functional remediation; Assigned to Arm(s): Functional remediation | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): Psychoeducation | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as Usual
D: Arm Label: Individual Placement and Support-vocational rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support-vocational rehabilitation | Arm Label: Vocational rehabilitation available at study site; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vocational rehabilitation available | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support-vocational rehabilitation; Assigned to Arm(s): Individual Placement and Support-vocational rehabilitation | Intervention Type: BEHAVIORAL; Name: Vocational rehabilitation available; Assigned to Arm(s): Vocational rehabilitation available at study site

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
Brief Summary: This is a prospective, multi-center, randomized, single-blind clinical trial conducted in the United States (US). The objective of the study is to evaluate the safety and efficacy of the HF Pressure Measurement System in reducing heart failure (HF) related hospitalizations in a subset of subjects suffering from HF.


Options:
A: Arm Label: Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice, Behavioral: Poor weather forecast warning | Arm Label: No Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD self care advice; Assigned to Arm(s): Forecast, No Forecast | Intervention Type: BEHAVIORAL; Name: Poor weather forecast warning; Assigned to Arm(s): Forecast
B: Arm Label: TREATMENT Group; Type: ACTIVE_COMPARATOR; Interventions: Device: HF Pressure Measurement System | Arm Label: CONTROL Group; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DEVICE; Name: HF Pressure Measurement System; Assigned to Arm(s): TREATMENT Group
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Activity monitoring and distance counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Activity monitoring and distance counseling | Intervention Type: BEHAVIORAL; Name: Activity monitoring and distance counseling; Assigned to Arm(s): Activity monitoring and distance counseling
D: Arm Label: MSU; Type: EXPERIMENTAL; Interventions: Procedure: MSU | Arm Label: OCCM; Type: ACTIVE_COMPARATOR; Interventions: Procedure: OCCM | Intervention Type: PROCEDURE; Name: MSU; Assigned to Arm(s): MSU | Intervention Type: PROCEDURE; Name: OCCM; Assigned to Arm(s): OCCM

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Tocilizumab (TCZ) Versus Placebo in Combination With Disease Modifying Antirheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
Brief Summary: This 2-arm study assessed the safety and efficacy of tocilizumab versus placebo, both in combination with disease modifying antirheumatic drugs (DMARDs), in regard to reduction in signs and symptoms, in patients with moderate to severe active rheumatoid arthritis with an inadequate response to DMARDs. Patients were randomized in a ratio of 2:1 to receive either tocilizumab 8 mg/kg intravenously (IV) or placebo IV every 4 weeks. All patients also received stable antirheumatic therapy, including permitted DMARDs. The anticipated time on study treatment was 3-12 months and the target sample size was 500+ individuals.


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Arm Label: Tocilizumab 8 mg/kg + DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Permitted DMARDs | Arm Label: Placebo + DMARDs; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Permitted DMARDs | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg + DMARDs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + DMARDs | Intervention Type: DRUG; Name: Permitted DMARDs; Assigned to Arm(s): Placebo + DMARDs, Tocilizumab 8 mg/kg + DMARDs
C: Arm Label: Tocilizumab + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: methotrexate | Arm Label: Tocilizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: placebo | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): Tocilizumab + Methotrexate, Tocilizumab + Placebo | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Tocilizumab + Methotrexate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Tocilizumab + Placebo
D: Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correlation of Donor Proinflammatory mRNA Profiles With Early Outcomes of Thoracic and Abdominal Transplantation
Brief Summary: Activity of genes in donor tissues that are involved in inflammation are thought to be involved with early organ dysfunction, increased immune responses in transplant recipients, and organ rejection. The purpose of this study is to determine the relationship between genetic expression in donor and recipient tissue with transplant survival. Participants in this study will have received heart, lung, liver, or kidney transplants.


Options:
A: Arm Label: Hypothermic oxygenated perfusion (HOPE); Type: ACTIVE_COMPARATOR; Interventions: Device: Hypothermic oxygenated perfusion (HOPE) | Arm Label: Control group: no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Hypothermic oxygenated perfusion (HOPE); Assigned to Arm(s): Hypothermic oxygenated perfusion (HOPE)
B: Arm Label: Hypothermic oxygenated perfusion (HOPE); Type: EXPERIMENTAL; Interventions: Device: Hypothermic oxygenated perfusion (HOPE) | Arm Label: Conventional cold storage (CCS); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional cold storage (CCS) | Intervention Type: DEVICE; Name: Hypothermic oxygenated perfusion (HOPE); Assigned to Arm(s): Hypothermic oxygenated perfusion (HOPE) | Intervention Type: PROCEDURE; Name: Conventional cold storage (CCS); Assigned to Arm(s): Conventional cold storage (CCS)
C: Arm Label: Kidney transplants; Type: N/A; Interventions: N/A | Arm Label: Liver transplants; Type: N/A; Interventions: N/A | Arm Label: Heart transplants; Type: N/A; Interventions: N/A | Arm Label: Lung transplants; Type: N/A; Interventions: N/A
D: Arm Label: Experimental: Hypothermic Machine Perfusion Group; Type: EXPERIMENTAL; Interventions: Device: The Medtronic Portable Bypass System (PBS®) | Arm Label: Matched control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: The Medtronic Portable Bypass System (PBS®); Assigned to Arm(s): Experimental: Hypothermic Machine Perfusion Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Trial for Surgical Treatment of Central Retinal Vein Occlusion - Radial Optic Neurotomy for CVO The ROVO Study
Brief Summary: The ROVO study is a prospective, placebocontrolled and randomised study designed to evaluate the effect of radial optic neurotomy in central vein occlusion, versus triamcinolone acetonide. 240 patients with a visual acuity \< 0.5 Snellen will be randomised. Patients are treated with either RON, or a single intravitreal injection of 4 mg triamcinolone acetonide, or a placebo treatment - a "sham" injection of intravitreal triamcinolone. Patients will be examined regularly over a period of one year.

Best corrected visual acuity for far and near, as well as clinical examinations, fluorescein- and indocyanine green angiograms, optical coherence tomography, and perimetry, are performed pre- and postoperatively.


Options:
A: Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: Ranibizumab injection 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.3 mg | Arm Label: Ranibizumab injection 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.3 mg; Assigned to Arm(s): Ranibizumab injection 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.5 mg; Assigned to Arm(s): Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Drug: ranibizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: Intravitreal Triamcinolone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Radial Optic Neurotomy; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Placebo - Sham Intravitreal Injection; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 2; Type: N/A; Interventions: N/A | Arm Label: 3; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 4; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 5; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 6; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 7; Type: N/A; Interventions: Other: Examination with an OCT device | Intervention Type: OTHER; Name: Examination with an OCT device; Assigned to Arm(s): 1, 3, 4, 5, 6, 7

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
Brief Summary: The purpose of this study is to assess the safety and efficacy of cediranib in combination with standard chemotherapy, in patients who have relapsed with ovarian, fallopian tube or epithelial cancer, after first line platinum based treatment.


Options:
A: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin
B: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide, Drug: celecoxib | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): Arm II
C: Arm Label: A (reference); Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: B (concurrent cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Arm Label: C (concurrent and maintenance cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Intervention Type: DRUG; Name: cediranib; Assigned to Arm(s): B (concurrent cediranib), C (concurrent and maintenance cediranib)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: brivanib | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: brivanib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
Brief Summary: The purpose of this study is to assess the safety and efficacy of cediranib in combination with standard chemotherapy, in patients who have relapsed with ovarian, fallopian tube or epithelial cancer, after first line platinum based treatment.


Options:
A: Arm Label: Niraparib monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Niraparib-bevacizumab combination; Type: EXPERIMENTAL; Interventions: Drug: Niraparib, Drug: Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Niraparib monotherapy, Niraparib-bevacizumab combination | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Niraparib-bevacizumab combination
B: Arm Label: A: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: C: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): B: Olaparib, C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A: Paclitaxel
C: Arm Label: A (reference); Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: B (concurrent cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Arm Label: C (concurrent and maintenance cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Intervention Type: DRUG; Name: cediranib; Assigned to Arm(s): B (concurrent cediranib), C (concurrent and maintenance cediranib)
D: Arm Label: Olaratumab and Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Arm Label: Liposomal Doxorubicin: Optional Olaratumab Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Intervention Type: BIOLOGICAL; Name: Olaratumab; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
Brief Summary: The purpose of this study is to assess the safety and efficacy of cediranib in combination with standard chemotherapy, in patients who have relapsed with ovarian, fallopian tube or epithelial cancer, after first line platinum based treatment.


Options:
A: Arm Label: A (reference); Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: B (concurrent cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Arm Label: C (concurrent and maintenance cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Intervention Type: DRUG; Name: cediranib; Assigned to Arm(s): B (concurrent cediranib), C (concurrent and maintenance cediranib)
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Arm C
C: Arm Label: Arm I (cabozantinib-s-malate); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib S-malate, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (paclitaxel); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm I (cabozantinib-s-malate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (cabozantinib-s-malate), Arm II (paclitaxel) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm II (paclitaxel)
D: Arm Label: Carboplatin and gemcitabine + bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Bevacizumab | Arm Label: Carboplatin and gemcitabine + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Carboplatin and gemcitabine + placebo

Answer: A